Holen Sie sich die Stockscreener-App
0.9947
2.16%
0.021
Handel nachbörslich:
.99
-0.0047
-0.47%
Schlusskurs vom Vortag:
$0.9737
Offen:
$0.96
24-Stunden-Volumen:
224.27K
Relative Volume:
0.36
Marktkapitalisierung:
$15.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.90M
KGV:
-0.00483
EPS:
-206.0125
Netto-Cashflow:
$-12.75M
1W Leistung:
-1.51%
1M Leistung:
+6.96%
6M Leistung:
-1.51%
1J Leistung:
+506.52%
1-Tages-Spanne:
$0.9554
$0.9992
1-Wochen-Bereich:
$0.945
$1.04
52-Wochen-Spanne:
$0.1131
$3.95
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Firmenname
Allarity Therapeutics Inc
Sektor
Branche
Telefon
401-426-4664
Adresse
24 SCHOOL ST., 2ND FLOOR, BOSTON
Vergleichen Sie ALLR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
0.9947 | 15.23M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Allarity Therapeutics Inc Aktie (ALLR) Neueste Nachrichten
How Allarity Therapeutics Inc. stock performs during market volatilityFree Stock Trading Community - Newser
What drives Allarity Therapeutics Inc. stock priceStrong return on investment - jammulinksnews.com
Is Allarity Therapeutics Inc. a good long term investmentTriple-digit wealth increases - Autocar Professional
What analysts say about Allarity Therapeutics Inc. stockTremendous return rates - Autocar Professional
Allarity Therapeutics Inc. Stock Analysis and ForecastFree Market Dynamics Reports - jammulinksnews.com
Will Allarity Therapeutics Inc. stock benefit from interest rate changesFree Stock Investment Growth Plan - beatles.ru
Does Allarity Therapeutics Inc. stock pay reliable dividendsRisk Adjusted Stock Signals - Newser
Allarity Therapeutics Secures New EU Commercial Agreement - TipRanks
Why Allarity Therapeutics Inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser
What makes Allarity Therapeutics Inc. stock price move sharplyReal Time Stock Signal - Newser
Allarity Therapeutics Announces New Licensing and - GlobeNewswire
Allarity Therapeutics Signs New Precision Oncology Licensing Deal for Breast Cancer | ALLR Stock News - Stock Titan
Allarity Therapeutics appoints Jeff Ervin as CFO - MSN
Jeffrey S. Ervin Appointed as Allarity’s New CFO - The Globe and Mail
Allarity Therapeutics appoints Jeff Ervin as new CFO By Investing.com - Investing.com Nigeria
Allarity Therapeutics, Inc. Announces Chief Financial Officer Changes - MarketScreener
Allarity Therapeutics appoints Jeffrey S. Ervin as part-time chief financial officer - Investing.com Nigeria
Allarity Therapeutics appoints Jeff Ervin as new CFO - Investing.com
Allarity Therapeutics Appoints Jeff Ervin To Succeed Alexander Epshinsky As CFO - Nasdaq
Allarity Therapeutics Appoints Jeff Ervin as New Chief Financial Officer - Nasdaq
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer - GlobeNewswire
Former NYSE Executive Takes CFO Role at Cancer Drug Developer Allarity Therapeutics - Stock Titan
Allarity Therapeutics Secures Australian Patent for DRP® Platform - The Globe and Mail
Allarity Therapeutics Advances Phase 2 Stenoparib Trial - TipRanks
Allarity Therapeutics receives patent acceptance in Australia for cancer diagnostic - Investing.com
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic - The Manila Times
Allarity Therapeutics Doses Second Patient in Phase 2 Ovarian Cancer Trial - MarketScreener
Allarity Therapeutics Holds Annual Stockholders Meeting - TipRanks
Allarity Therapeutics Stock Nears Yearly Low: A Trader’s High-Risk Analysis - thekhabrilal
Allarity Therapeutics, Inc Announces Changes to Board of Directors - MarketScreener
Allarity Therapeutics appoints pharma veteran Høiland to board - Investing.com India
Allarity Therapeutics Appoints Jesper Høiland to Board - TipRanks
Allarity Therapeutics appoints pharma veteran Høiland to board By Investing.com - Investing.com Nigeria
Allarity Therapeutics Announces Changes To Board Of Directors - MarketScreener
Finanzdaten der Allarity Therapeutics Inc-Aktie (ALLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):